tag/messge/

Breaking Biology Technology:Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4

[0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors [0] Quest Diagnostics Declares Quarterly Cash Dividend [0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease [0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics

Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2 New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2 New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3 New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7 China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8 PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 1 PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 2 PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 3 Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 1 Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 2 Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 3 Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 4 Back to normal 3A Surgery improves outcomes for spine patients 47438 1 Back to normal 3A Surgery improves outcomes for spine patients 47438 2

[0] Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline [0] New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals [0] China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009